Last reviewed · How we verify
Typherix
At a glance
| Generic name | Typherix |
|---|---|
| Sponsor | Helsinki University Central Hospital |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Study in Healthy Adults Aged 18-50 Yrs Administered With Hepatyrix or Havrix+Typherix or Tiphim Vi, to Compare Reactogenicity & Immunogenicity (PHASE3)
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adults, Children, Older Infants and Infants (PHASE2)
- Cross-reactive Immunity Elicited by Oral and Parenteral Typhoid Vaccines (PHASE4)
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Children, Older Infants and Infants (PHASE2)
- Extension Study of H01_04TP to Evaluate the Booster Response Induced by Vi-CRM197 in Adults (PHASE2)
- Safety and Immunogenicity of Three Formulations of Vi-CRM197 Vaccine Against S. Typhi in Adults (18-40 Years Old) (PHASE2)
- Safety and Immunogenicity of Vi-CRM197 Vaccine Against S. Typhi in Adult (18-40 Years Old) (PHASE1)
- Combined Vi Vaccination and Health Education Program on the Burden of Typhoid in Childhood (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |